The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://lucquia413913.wikiitemization.com/5561364/glp_3_retatrutide_a_comparative_analysis